HIV-specific CD8 T cells express low levels of IL-7Rα: Implications for HIV-specific T cell memory  by Wherry, E. John et al.
6) 366–373
www.elsevier.com/locate/yviroVirology 353 (200HIV-specific CD8 T cells express low levels of IL-7Rα:
Implications for HIV-specific T cell memory
E. John Wherry a,⁎,1, Cheryl L. Day b, Rika Draenert c, Joseph D. Miller a,
Photini Kiepiela d, Tonia Woodberry c, Christian Brander c, Marylyn Addo c,
Paul Klenerman b, Rafi Ahmed a, Bruce D. Walker c,⁎
a Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA
b Nuffield Department of Clinical Medicine, Peter Medawar Building, University of Oxford, UK
c Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
d HIV Pathogenesis Program, Doris Duke Medical Research Institute, University of KwaZulu Natal, Durban, South Africa
Received 17 March 2006; returned to author for revision 6 May 2006; accepted 2 June 2006
Available online 24 July 2006Abstract
Chronic infections in mice can result in defects in memory CD8 T cell properties including low expression of the IL-7Rα (CD127). To
determine whether defects in memory CD8 T cell formation exist during human chronic infections and to what extent these defects may be allele-
or epitope-specific, we compared influenza (Flu), vaccinia (VV) and EBV-specific CD8 T cells to HIV-specific CD8 T cells, using a panel of 13
HIV tetramers. Compared to Flu, VVor EBV, HIV tetramer+ CD8 T cells expressed significantly lower levels of CD127, and this reduction was
pervasive across all epitopes and alleles tested and over a wide range of viral loads and CD4 counts. These results indicate impaired HIV-specific
memory CD8 T cell differentiation, regardless of level of control of viremia, epitopes targeted or restricting HLA alleles.
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Chronic viral infections are often associated with loss of
virus-specific CD8 T cell effector functions (e.g. cytokine
production or cytotoxicity) (Wherry and Ahmed, 2004). Such
functional impairment has been observed in mouse models
(Fuller et al., 2004; Gallimore et al., 1998; Ou et al., 2001;
Wherry et al., 2003; Zajac et al., 1998; Zhou et al., 2002) and
also in humans (Goepfert et al., 2000; Greten et al., 1998;
Kelleher and Rowland-Jones, 2000; Kostense et al., 2001;
Lechner et al., 2000; Reignat et al., 2002; Shankar et al.,
2000; Trimble et al., 2000; Trimble and Lieberman, 1998;
Urbani et al., 2002; Vogel et al., 2001; Xiong et al., 2001).⁎ Corresponding authors.
E-mail addresses: jwherry@wistar.org (E.J. Wherry),
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doi:10.1016/j.virol.2006.06.017Recent studies in mice have found that virus-specific CD8 T
cells during chronic infections also fail to develop normal
memory CD8 T cell properties such as antigen-independent
persistence and homeostatic proliferation (Fuller et al., 2005;
Lang et al., 2005; Obar et al., 2004; Wherry et al., 2004). For
example, during chronic LCMV infection, virus-specific CD8
T cells are unable to respond to the homeostatic cytokines IL-
7 and IL-15 and their numbers decline when removed from
antigen (Wherry et al., 2004). These defects are in stark
contrast to the IL-7 and IL-15 dependent self-renewal and
maintenance of memory CD8 T cells following resolution of
an acute infection (Kaech et al., 2002; Schluns and
Lefrancois, 2003; Wherry and Ahmed, 2004). Substantial
reduction in the levels of IL-7 and IL-15 receptors during
chronic infection may be a central cause for the poor antigen-
independent memory T cell properties (Fuller et al., 2005;
Lang et al., 2005; Obar et al., 2004; Wherry et al., 2004). It
remains unclear, however, whether defects in memory CD8 T
cell maintenance pathways also arise during human chronic
Table 1
Patient characteristics
Patient identifier HIV status Antiretroviral therapy HIV viral load CD4 counts Location Responses analyzed
7 − NA NA Atlanta, GA Flu
14 − NA NA Atlanta, GA EBV
42 − NA NA Atlanta, GA EBV
55 − NA NA Atlanta, GA EBV
70 − NA NA Atlanta, GA
72 − NA NA Atlanta, GA EBV
82 − NA NA Atlanta, GA EBV
91 − NA NA Atlanta, GA VV, EBV
96 − NA NA Atlanta, GA EBV
97 − NA NA Atlanta, GA Flu, EBV, VV
116 − NA NA Atlanta, GA VV
141 − NA NA Atlanta, GA
K29 − NA NA Boston, MA EBV
K41 − NA NA Boston, MA EBV
K64 − NA NA Boston, MA EBV
L8154 + Yes <75 792 Boston, MA HIV
L859 + Yes 1021 589 Boston, MA HIV
161J + No <50 523 Boston, MA HIV
AAA + No 645 476 Boston, MA HIV
CR001m + Yes <50 ND Boston, MA HIV
PRLS23 + No 376,000 3 Boston, MA HIV
CR0014m + No 13,400 629 Boston, MA HIV
CR0154x + No 83,400 316 Boston, MA HIV
CR0154x + Yes <50 467 Boston, MA HIV
PRLS12 + No 160,000 60 Boston, MA HIV
PRLS12 + Yes <50 ND Boston, MA HIV
AT + No 290,000 129 Boston, MA HIV
AT + Yes <50 360 Boston, MA HIV
PRLS22 + No 750,000 24 Boston, MA HIV
PRLS22 + Yes <50 ND Boston, MA HIV
CR0023w + No 119,000 431 Boston, MA HIV
CR0023w + Yes <50 607 Boston, MA HIV
PS135 + No ND 277 Durban, South Africa HIV
PS158 + No ND 485 Durban, South Africa HIV
SK026 + No 2460 481 Durban, South Africa HIV
SK032 + No 74,800 183 Durban, South Africa HIV
SK036 + No 16,700 562 Durban, South Africa HIV
SK044 + No 114,000 276 Durban, South Africa HIV
SK048 + No 400 255 Durban, South Africa HIV
SK055 + No 63,100 615 Durban, South Africa HIV
SK075 + No 774 220 Durban, South Africa HIV
SK086 + No 1310 904 Durban, South Africa HIV
SK105 + No 49 838 Durban, South Africa HIV
SK114 + No 13,500 273 Durban, South Africa HIV
SK132 + No 32,500 179 Durban, South Africa HIV
SK150 + No 51,000 294 Durban, South Africa HIV
SK159 + No 32,200 344 Durban, South Africa HIV
SK163 + No 7930 740 Durban, South Africa HIV
SK169 + No 2120 442 Durban, South Africa HIV
SK177 + No 325,000 695 Durban, South Africa HIV
SK182 + No 24,800 336 Durban, South Africa HIV
SK187 + No 7910 533 Durban, South Africa HIV
SK191 + No 85,200 213 Durban, South Africa HIV
SK195 + No 43,000 364 Durban, South Africa HIV
SK197 + No 52,900 442 Durban, South Africa HIV
SK200 + No 97,600 423 Durban, South Africa HIV
SK205C + No 355,000 1021 Durban, South Africa HIV
SK214/A122 + No 51,700 216 Durban, South Africa HIV
SK222/A866 + No 8180 479 Durban, South Africa HIV
SK224/A005 + No 4210 389 Durban, South Africa HIV
SK231 + No 449,000 60 Durban, South Africa HIV
SK244 + No 25,600 432 Durban, South Africa HIV
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Table 2
Tetramers used in this study
Virus HLA allele Epitope
Influenza A2 GIL
Vaccinia A2 CLT
EBV A2 GLC
EBV B8 RAK
HIV A2 SL9
HIV A0205 GL9
HIV A3002 KIY9
HIV B8 FL8
HIV B8 EI8
HIV B42 RM9
HIV B42 TL9
HIV B42 YL9
HIV B57 KF11
HIV B81 RM9
HIV B81 TL9
HIV Cw0304 YL9
368 E.J. Wherry et al. / Virology 353 (2006) 366–373infections and whether there are allele- or epitope-specific
differences in memory CD8 T cell properties including IL-
7Rα expression.
In the current study, we have addressed this issue in humans
by comparing IL-7Rα (CD127) expression on CD8 T cells
specific for non-persisting human viruses (influenza virus (Flu)
and vaccinia virus (VV)), a latent infection (EBV) and for HIV-
specific CD8 T cells. Our results indicate that CD127
expression is significantly reduced on HIV-specific CD8 T
cells compared to CD8 Tcells specific for Flu, VVor EBV. Low
CD127 expression on HIV-specific CD8 T cells did not
correlate with viral load, CD4 count or the magnitude of the
epitope-specific CD8 T cell population examined. In addition,
low CD127 levels on HIV-specific CD8 T cells were found in
diverse patient cohorts from both the U.S. and South Africa
regardless of the epitope or restricting HLA allele. These results
suggest that reduced IL-7Rα expression on virus-specific CD8
T cells is a pervasive effect of chronic HIV infection. These
observations may have important implications for the develop-
ment of memory CD8 T cells during HIV infection and for
vaccination strategies designed to preserve HIV-specific CD8 T
cell responses.
Results and discussion
To investigate how HIV infection impacts the expression
of the IL-7Rα on virus-specific CD8 T cells, we assembled
cohorts of healthy controls subjects (HIV-negative; n=15)
and HIV-infected subjects from the U.S. (n=12) and South
Africa (n=30) (see Table 1). PBMC were screened for HIV-
specific CD8 T cell epitopes by ELISPOT as described
(Altfeld et al., 2000), and multiple HLA class I/peptide
tetramers were then constructed for the most frequently
targeted epitopes to identify CD8 T cells specific for HIV
(tetramers were constructed as described; Altman et al.,
1996). As controls, Flu, VV and EBV responses were
identified by screening PBMC from HIV-negative healthy
donors.
Using a panel of 17 tetramers (13 HIV, 1 Flu, 1 VV and 2
EBV; see Table 2), virus-specific CD8 T cell phenotype was
examined. CD27 is typically downregulated with progressive
T cell differentiation and CD27Lo T cells may represent
effectors cells (Appay et al., 2002; Hamann et al., 1997,
1999). The vast majority of tetramer+ CD8 T cells specific for
all 4 viruses expressed high levels of CD27 (Figs. 1A and B),
though the percentage of CD27+ cells was lower for both
EBV and HIV compared to Flu and VV (p<0.05). CD8 T cell
populations specific for HIV and EBV did not differ from
each other for CD27 expression. Flu and VV-specific CD8 T
cells also expressed high levels of CD62L. CD62L is
downregulated upon activation and often remains low for
long periods of time. Low levels of this molecule were
expressed by EBV and HIV-specific CD8 T cells compared to
Flu and VV-specific CD8 T cells (p<0.05; Figs. 1A and B).
Levels of CD62L were also significantly lower on HIV-
specific CD8 T cells when compared directly to EBV-specific
CD8 T cells (p<0.05; Fig. 1B). Thus, HIV-specific CD8 Tcells exhibit a largely CD27+ and CD62LLo phenotype
consistent with previous studies (Appay et al., 2002;
Champagne et al., 2001).
We next evaluated whether human virus-specific CD8 Tcells
responding to acute versus chronic infections differed in their
expression of CD127 (IL-7Rα). Flu and VV-specific CD8 T
cells expressed high levels of CD127; for all subjects, 80–97%
of the tetramer+ CD8 T cells were CD127+ (Figs. 2A and B).
For EBV-specific CD8 T cells, the levels of CD127 were
modestly, but significantly (p<0.01) reduced compared to Flu
and VV with a mean of ∼62% CD127+ (Figs. 2A and B).
During HIV infection, the vast majority of tetramer+ CD8 T
cells expressed low levels of CD127 (mean of ∼25% CD127+,
p<0.01 compared to all other groups; Figs. 2A and B). For each
of 13 tetramers tested in HIV-infected subjects, less than 50% of
the tetramer+ populations expressed high levels of CD127. In
fact, it was rare to find an HIV tetramer+ CD8 T cell population
that was >50% CD127+ (only 7/78 responses) and none was
more than 70% CD127+ in contrast to Flu and VV where the
vast majority of tetramer+ CD8 T cells were CD127+.
We next investigated whether there was any relationship
between different immunological or virological parameters and
CD127 expression by HIV-specific CD8 T cells. There was no
clear association between CD127 levels on HIV-specific CD8 T
cell populations and viral load (Fig. 3A). Though there was a
slight trend towards lower CD127 expression when viral load
(VL) was above 1×105 copies/ml and higher CD127 expression
in patients with undetectable virus, this was not statistically
significant and many subjects with suppressed viral replication
(VL <50 copies/ml) had predominantly CD127− tetramer+
CD8 T cell populations. Even in patients on antiretroviral
therapy (n=10 responses in 8 individuals), the majority of HIV-
specific CD8 T cell responses examined were predominantly
CD127Lo (filled symbols in Fig. 3). Furthermore, some subjects
with higher VL (∼>104 copies/ml) had >50% CD127+
tetramer+ CD8 T cells. It will be interesting in the future to
determine whether the duration of infection or epitope escape
mutations plays any role in the levels of CD127 expression on
HIV tetramer+ CD8 T cells. There was also no statistically
Fig. 1. Identification and characterization of human virus-specific CD8 Tcells. (A) CD27 and CD62L expression on Flu or HIV tetramer+ CD8+ Tcells is shown. The
percentage of influenza (Flu), vaccinia (VV), EBVor HIV tetramer+ CD8 T cells that expressed CD27 or CD62L is indicated. Horizontal lines indicate the average for
each group. For CD27, both EBVand HIV were lower than either Flu or VV (p<0.01 in pairwise t test comparisons), but EBVand HIV were not different from each
other (p>0.05). For CD62L, both EBV and HIV were lower than Flu or VV (p<0.01) and HIV was lower than EBV (p=0.03).
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CD8 T cells and CD4 counts (Fig. 3B) nor between CD127
expression and the magnitude (frequency of tetramer+ CD8 T
cells) of the epitope-specific CD8 T cell population (Fig. 3C).
Finally, HLA restriction alone did not appear to be a major
determinant of CD127 expression on HIV-specific CD8 T cells
since there was no significant difference between CD127
expression levels on tetramer+ CD8 Tcell populations restricted
by 7 different HLA types (Fig. 3D). This was true for HLA
types common in both U.S. and South African populations.
Together, the data presented indicate that HIV-specific CD8 T
cells have dramatically reduced CD127 expression compared to
CD8 T cells responding to non-persisting or latent viral
infections. Moreover, this low expression of CD127 by HIV-specific CD8 T cells appears to be pervasive across a range of
viral load, CD4 counts, virus-specific CD8 T cell population
size and HLA alleles.
The impact of chronic infections on memory CD8 T cell
development remains poorly understood. In humans, HIV-
specific CD8 T cells have been the subject of considerable
attention and studies have found that the memory T cell
differentiation state and function of HIV-specific CD8 T cells
are altered during HIV infection (Appay et al., 2002;
Champagne et al., 2001). Whether or not HIV-specific CD8
T cells develop into bona fide memory T cells capable of self-
renewal and other key memory T cell properties is an
important, but unresolved, issue. The expression of CD127
(IL-7Rα) plays a key role in antigen-independent memory
Fig. 2. Expression of CD127 (IL-7Rα) by human virus-specific CD8 T cells. Flu, VV, EBV and HIV-specific CD8 T cells were identified with HLA class I/peptide
tetramers and costained for CD127 expression. (A) Representative FACS plots for Flu, VV, EBV and HIV tetramer versus CD127 staining are shown. All plots are
gated on CD8+ Tcells, and the numbers indicate the percentage of CD127+ tetramer+ CD8 Tcells. (B) Summary of CD127 stains for Flu, VV, EBVand HIV tetramer+
CD8 T cells. Lines indicate the average for each group. p values for pairwise comparisons are indicated.
370 E.J. Wherry et al. / Virology 353 (2006) 366–373CD8 T cell homeostasis following acute infection or
vaccination (Goldrath et al., 2002; Kaech et al., 2003;
Schluns et al., 2000; Wherry et al., 2004). Defects in CD127
expression and IL-7 responsiveness appear to underlie
memory T cell defects in mice during chronic infections
(Fuller et al., 2005; Lang et al., 2005; Obar et al., 2004;Wherry et al., 2004). Recent studies in humans also suggest
that CD8 T cells specific for Flu and RSV, two viruses that
are cleared from the host, express higher levels of CD127
than CD8 T cells responding to the latent infections EBV and
CMV (van Leeuwen et al., 2005). Low CD127 expression on
HIV-specific CD8 T cells has recently been described using a
Fig. 3. Relationship of CD127 expression to immunological and virological parameters. Viral load, CD4 counts and HLA typing were performed in routine clinical
evaluation as described (Altfeld et al., 2000), and these data were compared to CD127 expression onHIV tetramer+CD8Tcells in each subject. CD127 expression (% of
tetramer+CD8Tcells) was plotted versus viral load (A), CD4Tcell counts (B) or percent of CD8Tcells that were tetramer+ (C). For parts A–C, lines indicate the best fit
linear regression analysis. In all cases, no significant correlation was observed. For part D, the percent CD127Hi tetramer+ CD8 Tcells was plotted for each of the 7 HLA
alleles studied. No significant difference was observed for any HLA allele (p>0.05 for all pairwise comparisons). Filled symbols indicate the subjects treated with
antiretroviral therapy.
371E.J. Wherry et al. / Virology 353 (2006) 366–373small number of HLA-A2 or -B8 tetramers (Boutboul et al.,
2005; Paiardini et al., 2005). However, neither of these
studies directly compared HIV-specific CD8 T cells to virus-
specific CD8 T cells responding to acute infections where
virus does not persist. In addition, whether low CD127
expression is consistent across multiple HLA alleles and in
different human populations remained unclear. The present
study confirms and extends these previous reports using 13
different HIV epitopes and 7 different HLA alleles and
subjects from diverse geographical regions (e.g. the U.S. and
South Africa). We also now provide a direct comparison of
HIV-specific CD8 T cells and CD8 T cells specific for Flu
and VV, two non-persisting infections. This direct comparison
demonstrates dramatically lower levels of CD127 expression
on HIV-specific CD8 T cells compared to CD8 T cells
specific for acute infections or EBV. Together, our observa-
tions and the earlier studies (Boutboul et al., 2005; Paiardini
et al., 2005; van Leeuwen et al., 2005) suggest that, during
human HIV infection, optimal IL-7Rα expression on virus-
specific CD8 T cells is not achieved.
In the current study, we have focused our analysis on only
HIV-specific CD8 T cells during HIV infection. An important
remaining question is whether or not reduced CD127
expression during HIV infection is restricted to virus-specific
CD8 T cells or is rather a global phenomenon affecting all T
cells. Both antigen stimulation and IL-7 (or IL-2) signaling
can reduce CD127 levels (Fry and Mackall, 2005; Kaech etal., 2003; Park et al., 2004), and loss of CD4 T cells during
HIV infection can lead to elevated circulating IL-7 levels in
humans (Fry and Mackall, 2005; Kaech et al., 2003; Park et al.,
2004). It is unclear how circulating IL-7 levels may impact
CD127 expression by HIV-specific CD8 T cells. In HIV+
subjects in the present study, a population of tetramer−
CD127+ CD8 T cells is clearly present and in some
subjects can represent more than 50% of total CD8 T cells
(see Fig. 2 and data not shown), suggesting that the mecha-
nism of low CD127 expression by HIV-specific CD8 T cells
may not universally impact all circulating CD8 T cells.
However, there is an overall reduction in the percentage of
total CD127+ CD8 T cells in HIV+ compared to HIV−
subjects (41.1%±2.3% versus 71.1%±4.0% respectively;
p<0.0001). This difference may reflect the expansion of
HIV-specific CD8 T cells, ongoing T cell responses to
concomitant or opportunistic infections or a more global
effect of HIV infections on T cells. Unfortunately, at the time
of this study, reagents to examine CD8 T cell responses to acute
infections (e.g. influenza virus) were not available for the South
African cohort and too few non-HIV-specific responses were
identified in the U.S. subjects to draw definitive conclusions
regarding the global or antigen-specific nature of CD127
downregulation. It will be important to address this question
in the future by examining CD8 T cells specific for non-
persisting viruses (e.g. Flu, VV, etc) in HIV-infected subjects
both in the U.S. and in South Africa.
372 E.J. Wherry et al. / Virology 353 (2006) 366–373Finally, our observations may have important implications
for the development of CD8 T cell memory during HIV
infection since efficient responsiveness to IL-7 is a key property
of antigen-independent memory CD8 T cells. Interestingly,
several groups have documented a substantial loss of HIV-
specific CD8 T cells following antiretroviral therapy or epitope
escape mutation where antigen levels are substantially reduced
or eliminated (Alter et al., 2003; Jamieson et al., 2003). Whether
low levels of CD127 contribute to this poor persistence of HIV-
specific CD8 T cells when antigen levels decline is currently
unclear. Future studies will be necessary to address how and
why CD127 levels remain low during HIV infection and
whether low CD127 expression impacts long-term HIV-specific
CD8 T cell maintenance.
Materials and methods
Patients
Healthy control subjects and HIV-infected patients were
recruited in Atlanta (Emory University), Boston (Partners AIDS
Research/Massachusetts General Hospital/Harvard University)
and South Africa (University of KwaZulu-Natal, Durban) with
institution review board approval, and all blood was obtained
and processed in accordance with institutional human subjects
and biosafety requirements. PBMC were obtained from healthy
controls (n=15) and HIV-infected subjects (n=42). For patient
characteristics, see Table 1.
Flow cytometry
PBMC were stained with HLA class I/peptide tetramers and
antibodies to phenotypic markers and analyzed by flow
cytometry as described (Kim et al., 2005). For a list of HLA
class I/peptide tetramers, see Table 2. HLA class I/peptide
tetramers were either purchased from Beckman Coulter or
produced as described (Altman et al., 1996).
Statistical analysis
Statistical analysis was performed using a pairwise t test or
ANOVA. For correlations, linear regression was performed
using Prism (GraphPad Software).
Acknowledgments
This work was supported by the National Institutes of Health
(R.A. and B.D.W.) and the Cancer Research Institute (E.J.W.),
the Doris Duke Charitable Foundation (B.D.W.) and the
Howard Hughes Medical Institute (B.D.W.). B.D.W. is the
recipient of a Doris Duke Distinguished Clinical Scientist
Award.
References
Alter, G., Hatzakis, G., Tsoukas, C.M., Pelley, K., Rouleau, D., LeBlanc, R.,
Baril, J.G., Dion, H., Lefebvre, E., Thomas, R., Cote, P., Lapointe, N., Routy,J.P., Sekaly, R.P., Conway, B., Bernard, N.F., 2003. Longitudinal assessment
of changes in HIV-specific effector activity in HIV-infected patients starting
highly active antiretroviral therapy in primary infection. J. Immunol. 171 (1),
477–488.
Altfeld,M.A., Trocha, A., Eldridge, R.L., Rosenberg, E.S., Phillips,M.N., Addo,
M.M., Sekaly, R.P., Kalams, S.A., Burchett, S.A., McIntosh, K., Walker,
B.D., Goulder, P.J., 2000. Identification of dominant optimal HLA-B60- and
HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid char-
acterization of CTL responses by enzyme-linked immunospot assay. J. Virol.
74 (18), 8541–8549.
Altman, J., Moss, P., Goulder, J., Barouch, D., McHeyzer-Williams, M., Bell, J.,
McMichael, A., Davis, M., 1996. Phenotypic analysis of antigen-specific T
lymphocytes. Science 274, 94–96.
Appay, V., Dunbar, P.R., Callan, M., Klenerman, P., Gillespie, G.M., Papagno,
L., Ogg, G.S., King, A., Lechner, F., Spina, C.A., Little, S., Havlir, D.V.,
Richman, D.D., Gruener, N., Pape, G., Waters, A., Easterbrook, P., Salio,
M., Cerundolo, V., McMichael, A.J., Rowland-Jones, S.L., 2002. Memory
CD8+ T cells vary in differentiation phenotype in different persistent virus
infections. Nat. Med. 8 (4), 379–385.
Boutboul, F., Puthier, D., Appay, V., Pelle, O., Ait-Mohand, H., Combadiere, B.,
Carcelain, G., Katlama, C., Rowland-Jones, S.L., Debre, P., Nguyen, C.,
Autran, B., 2005. Modulation of interleukin-7 receptor expression
characterizes differentiation of CD8 T cells specific for HIV, EBV and
CMV. AIDS 19 (17), 1981–1986.
Champagne, P., Ogg, G.S., King, A.S., Knabenhans, C., Ellefsen, K., Nobile,
M., Appay, V., Rizzardi, G.P., Fleury, S., Lipp, M., Forster, R., Rowland-
Jones, S., Sekaly, R.P., McMichael, A.J., Pantaleo, G., 2001. Skewed
maturation of memory HIV-specific CD8 T lymphocytes. Nature 410
(6824), 106–111.
Fry, T.J., Mackall, C.L., 2005. The many faces of IL-7: from lymphopoiesis to
peripheral T cell maintenance. J. Immunol. 174 (11), 6571–6576.
Fuller, M.J., Khanolkar, A., Tebo, A.E., Zajac, A.J., 2004. Maintenance, loss,
and resurgence of T cell responses during acute, protracted, and chronic viral
infections. J. Immunol. 172 (7), 4204–4214.
Fuller, M.J., Hildeman, D.A., Sabbaj, S., Gaddis, D.E., Tebo, A.E., Shang, L.,
Goepfert, P.A., Zajac, A.J., 2005. Cutting edge: emergence of CD127high
functionally competent memory T cells is compromised by high viral loads
and inadequate T cell help. J. Immunol. 174 (10), 5926–5930.
Gallimore, A., Glithero, A., Godkin, A., Tissot, A., Pluckthun, A., Elliott, T.,
Hengartner, H., Zinkernagel, R., 1998. Induction and exhaustion of
lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes
visualized using soluble tetrameric major histocompatibility complex class
I-peptide complexes. JEM 187, 1383–1393.
Goepfert, P.A., Bansal, A., Edwards, B.H., Ritter Jr., G.D., Tellez, I.,
McPherson, S.A., Sabbaj, S., Mulligan, M.J., 2000. A significant number
of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes
detected by tetramer binding do not produce gamma interferon. J. Virol. 74
(21), 10249–10255.
Goldrath, A.W., Sivakumar, P.V., Glaccum, M., Kennedy, M.K., Bevan, M.J.,
Benoist, C., Mathis, D., Butz, E.A., 2002. Cytokine requirements for
acute and basal homeostatic proliferation of naive and memory CD8+ T
cells. J. Exp. Med. 195 (12), 1515–1522.
Greten, T.F., Slansky, J.E., Kubota, R., Soldan, S.S., Jaffee, E.M., Leist,
T.P., Pardoll, D.M., Jacobson, S., Schneck, J.P., 1998. Direct visualiza-
tion of antigen-specific T cells: HTLV-1 Tax11–19-specific CD8(+) T
cells are activated in peripheral blood and accumulate in cerebrospinal
fluid from HAM/TSP patients. Proc. Natl. Acad. Sci. U. S. A. 95 (13),
7568–7573.
Hamann, D., Baars, P., Rep, M., Hooibrink, B., Kerkhof-Garde, S., Klein, M.,
van Lier, R., 1997. Phenotypic and functional separation of memory and
effector human CD8+ T cells. J. Exp. Med. 9, 1407–1418.
Hamann, D., Kostense, S., Wolthers, K.C., Otto, S.A., Baars, P.A., Miedema, F.,
van Lier, R.A., 1999. Evidence that human CD8+CD45RA+CD27− cells are
induced by antigen and evolve through extensive rounds of division. Int.
Immunol. 11 (7), 1027–1033.
Jamieson, B.D., Yang, O.O., Hultin, L., Hausner, M.A., Hultin, P., Matud, J.,
Kunstman, K., Killian, S., Altman, J., Kommander, K., Korber, B., Giorgi,
J., Wolinsky, S., 2003. Epitope escape mutation and decay of human
373E.J. Wherry et al. / Virology 353 (2006) 366–373immunodeficiency virus type 1-specific CTL responses. J. Immunol. 171
(10), 5372–5379.
Kaech, S.M., Wherry, E.J., Ahmed, R., 2002. Effector and memory T-cell
differentiation: implications for vaccine development. Nat. Rev., Immunol. 2
(4), 251–262.
Kaech, S.M., Tan, J.T., Wherry, E.J., Konieczny, B.T., Surh, C.D., Ahmed, R.,
2003. Selective expression of the interleukin 7 receptor identifies effector
CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4 (12),
1191–1198.
Kelleher, A.D., Rowland-Jones, S.L., 2000. Functions of tetramer-stained HIV-
specific CD4(+) and CD8(+) T cells. Curr. Opin. Immunol. 12 (4), 370–374.
Kim, A.Y., Lauer, G.M., Ouchi, K., Addo, M.M., Lucas, M., Wiesch, J.S.,
Timm, J., Boczanowski, M., Duncan, J.E., Wurcel, A.G., Casson, D.,
Chung, R.T., Draenert, R., Klenerman, P., Walker, B.D., 2005. The
magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend
on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood
105 (3), 1170–1178.
Kostense, S., Ogg, G.S., Manting, E.H., Gillespie, G., Joling, J., Vandenberghe,
K., Veenhof, E.Z., van Baarle, D., Jurriaans, S., Klein, M.R., Miedema, F.,
2001. High viral burden in the presence of major HIV-specific CD8(+) T cell
expansions: evidence for impaired CTL effector function. Eur. J. Immunol.
31 (3), 677–686.
Lang, K.S., Recher, M., Navarini, A.A., Harris, N.L., Lohning, M., Junt, T.,
Probst, H.C., Hengartner, H., Zinkernagel, R.M., 2005. Inverse correlation
between IL-7 receptor expression and CD8 T cell exhaustion during
persistent antigen stimulation. Eur. J. Immunol. 35 (3), 738–745.
Lechner, F., Wong, D.K., Dunbar, P.R., Chapman, R., Chung, R.T.,
Dohrenwend, P., Robbins, G., Phillips, R., Klenerman, P., Walker, B.D.,
2000. Analysis of successful immune responses in persons infected with
hepatitis C virus. J. Exp. Med. 191 (9), 1499–1512.
Obar, J.J., Crist, S.G., Leung, E.K., Usherwood, E.J., 2004. IL-15-independent
proliferative renewal of memory CD8+ T cells in latent gammaherpesvirus
infection. J. Immunol. 173 (4), 2705–2714.
Ou, R., Zhou, S., Huang, L., Moskophidis, D., 2001. Critical role for alpha/beta
and gamma interferons in persistence of lymphocytic choriomeningitis virus
by clonal exhaustion of cytotoxic T cells. J. Virol. 75 (18), 8407–8423.
Paiardini, M., Cervasi, B., Albrecht, H., Muthukumar, A., Dunham, R., Gordon,
S., Radziewicz, H., Piedimonte, G., Magnani, M., Montroni, M., Kaech,
S.M., Weintrob, A., Altman, J.D., Sodora, D.L., Feinberg, M.B., Silvestri,
G., 2005. Loss of CD127 expression defines an expansion of effector CD8+T
cells in HIV-infected individuals. J. Immunol. 174 (5), 2900–2909.
Park, J.H., Yu, Q., Erman, B., Appelbaum, J.S., Montoya-Durango, D., Grimes,
H.L., Singer, A., 2004. Suppression of IL7Ralpha transcription by IL-7 and
other prosurvival cytokines: a novel mechanism for maximizing IL-7-
dependent T cell survival. Immunity 21 (2), 289–302.
Reignat, S., Webster, G.J., Brown, D., Ogg, G.S., King, A., Seneviratne, S.L.,
Dusheiko, G., Williams, R., Maini, M.K., Bertoletti, A., 2002. Escaping
high viral load exhaustion: CD8 cells with altered tetramer binding in
chronic hepatitis B virus infection. J. Exp. Med. 195 (9), 1089–1101.Schluns, K.S., Lefrancois, L., 2003. Cytokine control of memory T-cell
development and survival. Nat. Rev., Immunol. 3 (4), 269–279.
Schluns, K.S., Kieper, W.C., Jameson, S.C., Lefrancois, L., 2000. Interleukin-7
mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat.
Immunol. 1 (5), 426–432.
Shankar, P., Russo, M., Harnisch, B., Patterson, M., Skolnik, P., Lieberman, J.,
2000. Impaired function of circulating HIV-specific CD8(+) T cells in
chronic human immunodeficiency virus infection. Blood 96 (9),
3094–3101.
Trimble, L.A., Lieberman, J., 1998. Circulating CD8 T lymphocytes in human
immunodeficiency virus-infected individuals have impaired function and
downmodulate CD3 zeta, the signaling chain of the T-cell receptor complex.
Blood 91 (2), 585–594.
Trimble, L.A., Kam, L.W., Friedman, R.S., Xu, Z., Lieberman, J., 2000.
CD3zeta and CD28 down-modulation on CD8 T cells during viral infection.
Blood 96 (3), 1021–1029.
Urbani, S., Boni, C., Missale, G., Elia, G., Cavallo, C., Massari, M., Raimondo,
G., Ferrari, C., 2002. Virus-specific CD8+ lymphocytes share the same
effector-memory phenotype but exhibit functional differences in acute
hepatitis B and C. J. Virol. 76 (24), 12423–12434.
van Leeuwen, E.M., de Bree, G.J., Remmerswaal, E.B., Yong, S.L., Tesselaar,
K., ten Berge, I.J., van Lier, R.A., 2005. IL-7 receptor alpha chain expression
distinguishes functional subsets of virus-specific human CD8+ T cells.
Blood 106 (6), 2091–2098.
Vogel, T.U., Allen, T.M., Altman, J.D., Watkins, D.I., 2001. Functional
impairment of simian immunodeficiency virus-specific CD8+ T cells during
the chronic phase of infection. J. Virol. 75 (5), 2458–2461.
Wherry, E.J., Ahmed, R., 2004. Memory CD8 T-cell differentiation during viral
infection. J. Virol. 78 (11), 5535–5545.
Wherry, E.J., Blattman, J.N., Murali-Krishna, K., van der Most, R., Ahmed, R.,
2003. Viral persistence alters CD8 T-cell immunodominance and tissue
distribution and results in distinct stages of functional impairment. J. Virol.
77 (8), 4911–4927.
Wherry, E.J., Barber, D.L., Kaech, S.M., Blattman, J.N., Ahmed, R., 2004.
Antigen-independent memory CD8 T cells do not develop during chronic
viral infection. Proc. Natl. Acad. Sci. U. S. A. 101 (45), 16004–16009.
Xiong, Y., Luscher, M.A., Altman, J.D., Hulsey, M., Robinson, H.L., Ostrowski,
M., Barber, B.H., MacDonald, K.S., 2001. Simian immunodeficiency virus
(SIV) infection of a rhesus macaque induces SIV-specific CD8(+) T cells
with a defect in effector function that is reversible on extended interleukin-2
incubation. J. Virol. 75 (6), 3028–3033.
Zajac, A.J., Blattman, J.N., Murali-Krishna, K., Sourdive, D.J., Suresh, M.,
Altman, J.D., Ahmed, R., 1998. Viral immune evasion due to persistence of
activated T cells without effector function (see comments). J. Exp. Med. 188
(12), 2205–2213.
Zhou, S., Ou, R., Huang, L., Moskophidis, D., 2002. Critical role for perforin-,
Fas/FasL-, and TNFR1-mediated cytotoxic pathways in down-regulation of
antigen-specific T cells during persistent viral infection. J. Virol. 76 (2),
829–840.
